Azathioprine or methotrexate added to adalimumab for Crohn’s
Treatments studied
Part of Digestive system clinical trials.
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and have Crohn’s disease for at least 6 weeks.
- Your Crohn’s symptoms are currently “active” and your study score is above 150 (CDAI).
- You have signs of active inflammation seen during a scope/colonoscopy (endoscopy score above 4).
- You are not responding to usual treatments, or you can’t tolerate them, or they are not safe for you—especially for starting adalimumab.
- You have not previously taken adalimumab, and you have not been unable to tolerate azathioprine or methotrexate in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
This trial compares a steroid called prednisolone to a special diet (aCDED with PEN) for treating Crohn's disease flare-ups. It aims to see which approach helps improve quality of life.
This study tests whether adding a special diet (called CDED) to a biologic medicine (infliximab or adalimumab) helps control Crohn's disease better than the medicine alone. It may reduce inflammation and improve symptoms.
This Phase 2 trial tests whether taking azithromycin (an antibiotic) before starting infliximab or adalimumab can reduce the chance your body rejects the anti‑TNF medicine. It may help some people get better and keep responding to treatment.
This study compares two treatment approaches for newly diagnosed moderate-to-severe Crohn's disease: a powerful biologic called mirikizumab given early (top-down) versus the standard approach with azathioprine. The goal is to see if starting with the stronger treatment leads to better control of inflammation and symptoms.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
Hear when a new Methotrexate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.